Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines
Abstract
Please see the Editorial Comment by Brent P. Little discussing this article.
BACKGROUND. Additional evidence of the role of COVID-19 vaccination in reducing pneumonia frequency and severity in the setting of breakthrough infection could help combat ongoing vaccine hesitancy.
OBJECTIVE. The purpose of this article was to compare the frequency and severity of pneumonia on chest CT in patients with confirmed COVID-19 between patients who are unvaccinated and those who are fully vaccinated by messenger RNA (mRNA) or adenovirus vector vaccines.
METHODS. This retrospective single-center study included 467 patients (250 men, 217 women; mean age, 65 ± 17 [SD] years) who underwent chest CT between December 15, 2021, and February 18, 2022, during hospitalization for symptomatic COVID-19, confirmed by reverse transcriptase–polymerase chain reaction assay. A total of 216 patients were unvaccinated, and 167 and 84 patients were fully vaccinated (defined as receipt of the second dose at least 14 days before COVID-19 diagnosis) by the BNT162b2 mRNA vaccine or the ChAdOx1-S adenovirus vector vaccine, respectively. Semiquantitative CT severity scores (CT-SS; 0–25 scale) were determined; CT-SS of 0 indicated absence of pneumonia. Presence of bilateral involvement was assessed in patients with pneumonia. Associations were explored between vaccination status and CT findings.
RESULTS. The frequency of the absence of pneumonia was 15% (32/216) in unvaccinated patients, 29% (24/84) in patients fully vaccinated with ChAdOx1-S vaccine, and 51% (85/167) in patients fully vaccinated with BNT162b2 vaccine (unvaccinated and ChAdOx1-S vs BNT162b2: p < .001; unvaccinated vs ChAdOx1-S: p = .08). Mean CT-SS was significantly higher in unvaccinated patients (9.7 ± 6.1) than in patients fully vaccinated with BNT162b2 (5.2 ± 6.1) or ChAdOx1-S (6.2 ± 5.9) vaccine (both p < .001). Full vaccination was significantly associated with CT-SS independent of patient age and sex (estimate = −4.46; p < .001). Frequency of bilateral lung involvement was significantly higher in unvaccinated patients (158/184, 86%) and in patients fully vaccinated with ChAdOx1-S vaccine (54/60, 90%) than in patients fully vaccinated with BNT162b2 vaccine (47/82, 57%) (both p < .001).
CONCLUSION. Pneumonia frequency and severity were lower in patients with full vaccination by mRNA and adenovirus vector vaccines who experienced breakthrough infections in comparison with unvaccinated patients.
CLINICAL IMPACT. The visual observation by radiologic imaging of the protective effect of vaccination on lung injury in patients with breakthrough infections provides additional evidence supporting the clinical benefit of vaccination.
HIGHLIGHTS
Key Finding
▪ Frequency of pneumonia absence was 15% in unvaccinated patients versus 51% and 29% in patients fully vaccinated with BNT162b2 and ChAdOx1-S vaccines, respectively. Mean CT-SS was significantly higher in unvaccinated patients (9.7 ± 6.1) than patients fully vaccinated with BNT162b2 (5.2 ± 6.1) or ChAdOx1-S (6.2 ± 5.9) (both p < .001).
Importance
▪ Evaluation of chest CT findings provides an additional approach for demonstrating the effectiveness of different COVID-19 vaccines in reducing the impact of a COVID-19 diagnosis.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
WHO website. COVID-19 weekly epidemiological update. www.who.int/publications/m/item/covid-19-weekly-epidemiological-update. Accessed March 5, 2022
2.
Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data website. ourworldindata.org/coronavirus. Accessed March 5, 2022
3.
Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol 2022; 22:57–65
4.
Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med 2021; 385:320–329
5.
Elmokadem AH, Mounir AM, Ramadan ZA, Elsedeiq M, Saleh GA. Comparison of chest CT severity scoring systems for COVID-19. Eur Radiol 2022; 32:3501–3512
6.
Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30:6808–6817
7.
Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol 2020; 30:4407–4416
8.
Salaffi F, Carotti M, Tardella M, et al. The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. Medicine (Baltimore) 2020; 99:e22433
9.
Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020; 55:327–331
10.
Yang R, Li X, Liu H, et al. Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiol Cardiothorac Imaging 2020; 2:e200047
11.
Wasilewski PG, Mruk B, Mazur S, Półtorak-Szymczak G, Sklinda K, Walecki J. COVID-19 severity scoring systems in radiological imaging: a review. Pol J Radiol 2020; 85:e361–e368
12.
Verma A, Kumar I, Singh PK, et al. Initial comparative analysis of pulmonary involvement on HRCT between vaccinated and non-vaccinated subjects of COVID-19. Eur Radiol 2022; 32:4275–4283
13.
Lee JE, Hwang M, Kim YH, et al. Imaging and clinical features of COVID-19 breakthrough infections: a multicenter study. Radiology 2022; 303:682–692
14.
Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open 2021; 11:e044640
15.
Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021; 11:22777
16.
Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295:715–721
17.
Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246:697–722
18.
Hallgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol 2012; 8:23–34
19.
Landis JR, Koch GG. A one-way components of variance model for categorical data. Biometrics 1977; 33:671–679
20.
Hefeda MM. CT chest findings in patients infected with COVID-19: review of literature. Egypt J Radiol Nucl Med 2020; 51:239
21.
Feng Z, Yu Q, Yao S, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun 2020; 11:4968
22.
Huang G, Gong T, Wang G, et al. Timely diagnosis and treatment shortens the time to resolution of coronavirus disease (COVID-19) pneumonia and lowers the highest and last CT scores from sequential chest CT. AJR 2020; 215:367–373
23.
Baeis MG, Mozafari A, Movaseghi F, et al. The crazy-paving pattern in chest CT imaging of COVID-19 patients: an alarming sign for hospitalization. Iran J Radiol 2021; 18:113286
24.
Bellos I, Tavernaraki K, Stefanidis K, et al. Chest CT severity score and radiological patterns as predictors of disease severity, ICU admission, and viral positivity in COVID-19 patients. Respir Investig 2021; 59:436–445
25.
Li Y, Yang Z, Ai T, Wu S, Xia L. Association of “initial CT” findings with mortality in older patients with coronavirus disease 2019 (COVID-19). Eur Radiol 2020; 30:6186–6193
26.
Kim C, Kim JY, Lee EJ, et al. Clinical findings, viral load, and outcomes of COVID-19: comparison of patients with negative and positive initial chest computed tomography. PLoS One 2022; 17:e0264711
27.
Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARSCoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 2021; 27:790–792
28.
Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARSCoV-2. Nat Med 2022 Apr 8 [published online]
29.
Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Chest CT imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence. Chest 2020; 158:1885–1895
30.
Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. RadioGraphics 2020; 40:1848–1865
31.
Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 2022; 386:340–350
32.
Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK website. medRxiv website.. Published October 6, 2021. Accessed March 30, 2022
33.
European Centre for Disease Prevention and Control website. SARS-CoV-2 variants of concern as of 3 February 2022. www.ecdc.europa.eu/en/covid-19/variants-concern. Accessed May 9, 2022
Information & Authors
Information
Published In
Copyright
© American Roentgen Ray Society.
History
Submitted: April 13, 2022
Revision requested: April 29, 2022
Revision received: May 13, 2022
Accepted: May 24, 2022
Version of record online: June 1, 2022
Keywords
Authors
Metrics & Citations
Metrics
Citations
Export Citations
To download the citation to this article, select your reference manager software.